Development and Evaluation of Serum CST1 Detection for Early Diagnosis of Esophageal Squamous Cell Carcinoma

被引:15
|
作者
Wang, Jianwei [1 ,2 ]
Yu, Lili [1 ,3 ]
Sun, Yulong [4 ]
Zhang, Liangming [1 ,3 ]
Tu, Mingshu [1 ,3 ]
Cai, Liqing [1 ,3 ]
Yin, Xiaoqing [3 ,5 ]
Pan, Xiaojie [1 ,6 ]
Wang, Tao [4 ]
Huang, Yi [1 ,3 ,7 ,8 ]
机构
[1] Fujian Med Univ, Prov Clin Coll, Fuzhou 350001, Peoples R China
[2] Fujian Prov Hosp, Dept Clin Lab, South Branch, Fuzhou 350008, Peoples R China
[3] Fujian Prov Hosp, Dept Clin Lab, Fuzhou 350001, Peoples R China
[4] Shanghai Liangrun Biomed Technol Ltd Co, Shanghai 200000, Peoples R China
[5] Fujian Univ Tradit Chinese Med, Integrated Chinese & Western Med Coll, Fuzhou 350001, Peoples R China
[6] Fujian Prov Hosp, Dept Thorac Surg, Fuzhou 350001, Peoples R China
[7] Fujian Prov Hosp, Cent Lab, Fuzhou 350001, Peoples R China
[8] Fujian Prov Hosp, Ctr Expt Res Clin Med, Fuzhou 350001, Peoples R China
来源
CANCER MANAGEMENT AND RESEARCH | 2021年 / 13卷
关键词
esophageal squamous cell carcinoma; cystatin SN; chemiluminescence enzyme immunoassay; methodological evaluation; early diagnosis; CYSTATIN SN; EXPRESSION; IDENTIFICATION; INHIBITOR; BIOMARKER;
D O I
10.2147/CMAR.S337497
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: Our pilot study has shown that cystatin SN (CST1) protein is highly expressed in esophageal squamous cell carcinoma (ESCC) tissues. We intend to develop a chemiluminescent enzyme immunoassay (CLEIA) available for serum CST1 detection and define the diagnostic value of CST1 detection for early ESCC patients, and establish a panel of CST1 with traditional tumor markers to improve the diagnostic sensitivity for early ESCC. Methods: Detection performance of CLEIA for CST1 was evaluated by linearity, detection limit, accuracy, precision, anti-interference and stability. Diagnostic performance of CST1 for early ESCC was evaluated by detecting CST1 of 112 early ESCC, 107 esophageal benign lesions (EBL), and 151 healthy controls (HC). CEA, CYFRA21-1 and SCC-Ag were detected by chemiluminescence immunoassay (CLIA). Results: The linear range and detection limit of CLEIA for CST1 were 6.25-400 pg/mL and 1.35 pg/mL, respectively; the average recovery rate was 102.65%; CVs of intra-batch precision and inter-batch precision were <1/4 TEa and <1/3 TEa, respectively; 8 interferents including 7 common interferents and CST4 had no interference on CST1 detection; stability evaluation showed good sample and reagent stability. The level and positive rate of CST1 in early ESCC group were significantly higher than those in EBL/HC groups (P 0.05). The diagnostic sensitivity of CST1 for early ESCC was 31.25% (specificity 92.64%, AUC 0.654). The diagnostic sensitivity of traditional tumor markers ranged from 16.07% to 28.57%, at 93.0% specificity, and SCC-Ag showed the highest AUC (0.709). Combination of CST1 and CEA, SCC-Ag exhibited the highest AUC up to 0.736 (sensitivity 49.11%, specificity 89.53%). Conclusion: CLEIA has excellent detection performance for CST1. CST1 might be a prospective serological biomarker for early diagnosis of ESCC, while combination of CST1 and CEA, SCC-Ag might improve the early diagnostic performance.
引用
收藏
页码:8341 / 8352
页数:12
相关论文
共 50 条
  • [21] A comparison of serum Cyfra 21-1 and SCC AG in the diagnosis of squamous cell esophageal carcinoma
    Ychou, M
    Khemissa-Akouz, F
    Kramer, A
    Senesse, P
    Grenier, J
    BULLETIN DU CANCER, 2001, 88 (10) : 1023 - 1027
  • [22] Serum Autoantibodies against STIP1 as a Potential Biomarker in the Diagnosis of Esophageal Squamous Cell Carcinoma
    Xu, Yi-Wei
    Liu, Can-Tong
    Huang, Xin-Yi
    Huang, Li-Sheng
    Luo, Yu-Hao
    Hong, Chao-Qun
    Guo, Hai-Peng
    Xu, Li-Yan
    Peng, Yu-Hui
    Li, En-Min
    DISEASE MARKERS, 2017, 2017
  • [23] Diagnosis and therapy of esophageal squamous cell dysplasia and early esophageal squamous cell cancer
    Subramanian, Charumathi Raghu
    Triadafilopoulos, George
    GASTROENTEROLOGY REPORT, 2017, 5 (04): : 247 - 257
  • [24] Detection of multiple gene hypermethylation in the development of esophageal squamous cell carcinoma
    Nie, Y
    Liao, J
    Zhao, X
    Song, YL
    Yang, GY
    Wang, LD
    Yang, CS
    CARCINOGENESIS, 2002, 23 (10) : 1713 - 1720
  • [25] PATHOLOGY OF EARLY ESOPHAGEAL SQUAMOUS CELL CARCINOMA
    Tumor Prevention
    Treatment and Research Group
    Chengchow
    Honan
    Esophageal Cancer Research Group
    Chinese Academy of Medical Sciences
    Peking
    and Linhsien County People's Hospital
    Honan
    CHINESE MEDICAL JOURNAL, 1977, (03)
  • [27] Combined detection of serum Dickkopf-1 and its autoantibodies to diagnose esophageal squamous cell carcinoma
    Peng, Yu-Hui
    Xu, Yi-Wei
    Li, En-Min
    Xu, Li-Yan
    CANCER RESEARCH, 2016, 76
  • [28] Combined detection of serum Dickkopf-1 and its autoantibodies to diagnose esophageal squamous cell carcinoma
    Peng, Yu-Hui
    Xu, Yi-Wei
    Guo, Hong
    Huang, Li-Sheng
    Tan, Hua-Zhen
    Hong, Chao-Qun
    Li, Shan-Shan
    Xu, Li-Yan
    Li, En-Min
    CANCER MEDICINE, 2016, 5 (07): : 1388 - 1396
  • [29] Evaluation of 2 Commercially Systems for Detection of Serum Squamous Cell Carcinoma Antigen in Pan Squamous Cell Carcinoma
    Chen, Hao
    Tian, Liru
    Chen, Jiahong
    Sun, Peng
    Han, Runkun
    Wu, Xingping
    Dai, Shuqin
    CANCER CONTROL, 2020, 27 (01)
  • [30] Significance of Background Coloration in Endoscopic Detection of Early Esophageal Squamous Cell Carcinoma
    Minami, H.
    Isomoto, H.
    Inoue, H.
    Akazawa, Y.
    Yamaguchi, N.
    Ohnita, K.
    Takeshima, F.
    Hayashi, T.
    Nakayama, T.
    Nakao, K.
    DIGESTION, 2014, 89 (01) : 6 - 11